Obsidian Therapeutics公司今日重磅宣布，其针对晚期黑色素瘤的细胞疗法——Amsoki-Cel（原名Obx-115），在1/2期Agni-01研究的注册导向队列中，已成功完成首例患者入组。这一里程碑事件，标志着该创新疗法正式迈入关键性临床开发阶段，为全球黑色素瘤患者带来了全新的治疗希望。
Obsidian Therapeutics公司今日重磅宣布，其针对晚期黑色素瘤的细胞疗法——Amsoki-Cel（原名Obx-115），在1/2期Agni-01研究的注册导向队列中，已成功完成首例患者入组。这一里程碑事件，标志着该创新疗法正式迈入关键性临床开发阶段，为全球黑色素瘤患者带来了全新的治疗希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.